NHS Fit for the Future Dementia Challenge 2026: Fully Funded Real-World Evaluation

The NHS fit for the future dementia challenge was a UK Research and Innovation (UKRI) and Medical Research Council (MRC) funding opportunity for clinical interventions and technological innovations that could improve dementia diagnosis or help clinicians identify meaningful change after diagnosis. The official UKRI page now marks the opportunity Closed. Its closing date was 4 June 2026 at 4:00pm UK time, so this page is retained as a historical reference rather than presented as an open route to apply.

The opportunity was aimed at a particular gap in dementia care: innovations that can help the NHS shorten the time from referral to diagnosis, improve the way disease stage or prognosis is understood, or identify clinical change early enough for care teams to respond. The challenge also sought solutions capable of NHS deployment from 2029. That did not mean that a product could be a loose concept. The official criteria required evidence, user testing, an implementation plan, and a credible route through clinical, regulatory, and operational work.

At a glance

There was no simple cash award amount published on the official opportunity page. UKRI describes the benefit as a fully funded real-world evaluation tailored to produce evidence for wider adoption across the UK. That evaluation could include clinical research infrastructure, protocol development, monitoring, data collection, analysis, reporting, and dissemination. The page estimated that an evaluation would begin at the start of 2027 and could run for up to two years. It also listed support for fast-track UK regulatory clearance, commissioning and procurement guidance, and development of an NHS market-access strategy across the devolved nations.

What the challenge was looking for

The challenge was connected to the R&D Missions Accelerator Programme Health Mission. UKRI said the ambition was to identify, develop, validate, and implement innovations with the potential to help ensure that, by 2029, 92% of patients referred for dementia assessment receive a diagnosis within 18 weeks of referral.

Applicants needed to show a clear connection to at least one of the stated goals:

• shortening the time to dementia diagnosis;
• enhancing early detection of clinical change following diagnosis; or
• making an intervention or innovation capable of NHS deployment from 2029.

For a clinical intervention, the official page required evaluation in at least a single-site pilot. The intervention also needed to deliver at least one concrete benefit, such as a shorter referral-to-diagnosis pathway, improved staging of disease state, better prognostic information for patient and carer support, lower resource requirements, improved operational efficiency, or better patient outcomes.

For a technological innovation, UKRI required a narrower and more developed proposition. The technology had to be intended for dementia diagnosis or for tracking disease progression in people already living with a dementia diagnosis. It had to be a medical device or an in vitro diagnostic and either have, or be near to, UKCA or CE regulatory clearance. If it was not already cleared for sale in the UK, the applicant needed a roadmap and delivery plan to achieve regulatory clearance no later than the end of March 2029. The page also required evidence of clinical safety and efficacy through randomised controlled trial data or clinically robust real-world evidence.

These requirements matter for anyone using the historical listing to assess fit for a similar future call. A general-purpose dementia app, an early research idea without clinical evidence, or a tool that only collects data would not automatically meet the published standard. The proposal needed to explain the clinical decision or care pathway it would improve, the evidence already available, and the work still needed before routine NHS use.

Shared requirements for interventions and technologies

Regardless of format, every proposed intervention or innovation had to be tested with user groups. That requirement points beyond technical usability testing alone. A credible submission would need to show that the people expected to use the intervention—such as memory-clinic staff, primary-care professionals, community teams, patients, or carers—had informed its design and could use it in the intended setting.

UKRI also required the proposal to be scalable for routine use across the NHS and to include a clear roadmap for implementation. That roadmap needed to address the practical work between a positive evaluation and adoption: service ownership, workflow changes, training, support, information governance, data handling, procurement, and the resources required for ongoing use.

Every proposal needed the support of a clinical champion who could support the real-world evaluation and, subject to milestone completion, rollout at scale and pace across the UK. Applicants also had to demonstrate that they understood the resources needed to train users and support adoption, and they had to articulate the value proposition for stakeholders. Evidence of efficiency gains or health-economic benefit was desirable, even though the page did not describe it as an absolute eligibility requirement.

Commercial organisations had an additional commitment. Alongside the intervention or innovation, they were expected to provide training, clinical support, and technical support for the duration of the evaluation period, up to two years, at zero cost. A company considering a future opportunity with similar terms should therefore budget its staff time, in-field support, documentation, maintenance, and clinical engagement separately from product development.

Who could take part

The official page said that healthcare professionals, businesses, and researchers could take part. Businesses had to be UK-based legal entities. Healthcare practitioners and researchers had to be based at an eligible organisation in the UK. UKRI directed applicants to its organisational eligibility guidance and asked them to email the Health Team if an application was supported by a part of the organisation based outside the UK.

The opportunity also allowed project partners with an integral role in the proposed innovation or intervention. A project partner could contribute cash or in-kind support, including staff time, equipment, sites or facilities, data, software or materials, recruitment of research participants, or human-tissue samples. Each named project partner needed to provide a statement of support.

There were boundaries around those roles. An individual in the application core team could not also be a project partner. An organisation employing a core-team member could not be a project-partner organisation, including another department within the same organisation. If people from the same organisation were collaborating, UKRI said they should instead be included in the core team as a project co-lead or specialist.

What successful proposals would receive

The published benefit was an evaluation package, not a stated unrestricted grant pot. UKRI said that successful clinical interventions and technological innovations would receive a fully funded real-world evaluation tailored to generate evidence for widespread adoption across the UK.

The package could include a partnership with a clinical research lead and clinical infrastructure; collaborative protocol development; evaluation monitoring; data collection and analysis support; write-up and dissemination; and access to evaluation data for analysis and modelling that could support product or service improvement. It could also include support for fast-track regulatory clearance in the UK, guidance on commissioning and procurement, and help developing a market-access strategy for the NHS across the devolved nations.

UKRI noted that two successful technologies or interventions might be evaluated together when they could complement one another in clinical practice. The example given was a new approach to brain imaging paired with an automated image-analysis tool. That possibility reinforces the need to describe the care pathway, interfaces, responsibilities, and evidence plan clearly enough for a combined evaluation to be feasible.

How the application route worked

This was not an open, direct-to-full-application competition. The official page described it as invitation only and stated that applicants had to complete a mandatory Expression of Interest first. UKRI used the EOI to check eligibility for the full application stage. Only applicants invited after a successful EOI could proceed.

For invited applicants, UKRI said that the start-application link would be provided by email. The full application was run through the new UKRI Funding Service, not the Joint Electronic Submissions system. The project lead was responsible for completing the application, while team members and project partners were expected to contribute. Only the lead organisation could submit to UKRI.

The published application steps were:

1. Confirm that the applicant is the project lead.
2. Sign in or create a UKRI Funding Service account, select the organisation, verify the email address, and set a password.
3. Answer the application questions in the Funding Service, saving work as needed and following any document-upload instructions.
4. Check the application in read-only view before sending it to the research office, where applicable.
5. Send the completed application to the research office for checking, if applicable, and revise it if returned for edits.
6. Where applicable, the research office submits the checked application to UKRI. Businesses and organisations without a research office could submit directly and disregard the internal-check steps.

The full application asked for a lay case for support, a description of the intervention or innovation and clinical need, evidence and evaluation plans, regulatory status for technology innovations, team capability, resources available for the evaluation, organisational support, project-partner details and letters, and relevant responsible-research information. The resource section was especially important because UKRI was funding the evaluation work: applicants had to describe their own contribution, such as products, software, training resources, in-field support, seconded staff, or access to background data.

What to take from this historical opportunity

The strongest lesson is that this challenge was an evidence-and-implementation opportunity rather than an idea-stage accelerator. A future applicant would need a defined clinical problem, a tested intervention, and a realistic plan for how the NHS would use it. For a clinical pathway change, that meant at least a single-site pilot and measurable improvement. For a medical device or IVD, it meant clinical safety and efficacy evidence plus a regulatory route. For both, it meant user testing, a clinical champion, implementation planning, and a credible account of training and support.

The closed status also changes what a reader should do with this page. There is no current deadline to apply through the official listing, no confirmed next round recorded on the verified source, and no basis for treating the 2026 date as an active submission window. Readers should use the UKRI page for any later announcement and should not assume that a future dementia challenge will preserve the same eligibility rules, evidence thresholds, or evaluation terms.

Official source and archive note

The official source is the UKRI Funding Finder page for the NHS fit for the future dementia challenge: https://www.ukri.org/opportunity/nhs-fit-for-the-future-dementia-challenge/. UKRI is the organisation named as a funder on that page, alongside the Medical Research Council. The page currently reports the opportunity as closed and records the closing date as 4 June 2026 at 4:00pm UK time. This entry keeps that real closing date in its metadata and marks the page as a historical reference so it is clear that the cycle has ended.